Pre-meeting Session:
PW2. Vincent T. Andriole ID Board Review Course $
Tuesday, October 1, 2013: 8:00 AM-5:00 PM
Room: The Moscone Center: 132-133 (Hall E)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss and apply updated information on diagnosis and treatment of sexually transmitted diseases
  • summarize and apply latest treatments for central nervous system (CNS) infections: meningitis and encephalitis
  • discuss and apply updated information on diagnosis and treatment of hepatitis
  • discuss the most current diseases of travelers and apply updates to patient care
  • critically assess available data and implement strategies to support infection control in healthcare settings
  • determine best treatments for transplant-associated infections
  • discuss current information on diagnosing and treating mycobacterial infections
  • assess and apply current trends in HIV care
  • assess and apply current information regarding diagnosis and treatment of non-HIV viral infections
  • assess causes and devise effective management of GI infections
  • discuss and apply updated information on noon-infectious causes of fever
  • discuss the causes and treatment modalities of zoonotic infections

Target Audience: members-in-training, infectious diseases physicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Pre-Meeting Workshop Moderators:  Janet Gilsdorf, MD, FIDSA, University of Michigan Medical Center and Rafael Campo, MD, FIDSA, University of Miami

Presentations:

8:01 AM
Viral Hepatitis
Eliot W. Godofsky, MD

8:40 AM

9:20 AM
Travel Medicine Potpourri
Thomas Moore, MD, FIDSA

10:00 AM

10:15 AM
Infections in Transplant Patients
Barbara Alexander, MD, MHS, FIDSA

10:55 AM
Non-Infectious Causes of Fever
Bennett Lorber, MD, DSc (hon), FIDSA, MACP

11:35 AM
Zoonoses
Joseph Vinetz, MD, FIDSA

12:15 PM

12:45 PM
Sexually Transmitted Infections
Khalil Ghanem, MD, PhD, FIDSA

1:25 PM
HIV Update
Roy M. Gulick, MD, FIDSA

2:05 PM
Mycobacterial Infections
Jeffrey Starke, MD, FIDSA

2:45 PM

3:00 PM
Topics in Infection Prevention
Trish M. Perl, MD, MSc, FIDSA, FSHEA

3:40 PM
Viral Infections
Andrew Pavia, MD, FIDSA, FSHEA

4:20 PM
GI Infections
Edward T. Ryan, MD, DTMH, FIDSA

CME Credits: Maximum of 7.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this workshop.

ACPE Number:

Disclosures:

J. Gilsdorf, Am Board of Pediatrics: Board Member and Member, sub-board of Peds ID, ABP, Consulting fee

R. Campo, Gilead Sciences: Grant Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Grant Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Wife is an employee and shareholder of Merck, Dividends and Salary
Abbott: Shareholder, Dividends
Abbvie: Shareholder, Dividends

K. Ghanem, None

B. Alexander, Optimer: Investigator, Research support
Astellas: Investigator, Research support
Charles river laboratories: Investigator, Research support
Virapharma: Investigator, Research support

B. Lorber, None

T. Moore, None

J. Vinetz, None

R. M. Gulick, Janssen: Grant Investigator, Research grant
Pfizer: Grant Investigator, Research grant
ViiV: Grant Investigator, Research grant

E. W. Godofsky, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator, Research support
Boeringer-Ingelheim: Investigator, Research support
Vertex Pharmaceutical: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead Pharmaceutical: Investigator, Research support
Novartis: Investigator, Research support
Genentech: Scientific Advisor, Consulting fee
Anadys Pharmaceutical: Investigator, Research support
Idenix Pharmaceutical: Investigator, Research support
Janssen Pharmaceutical: Investigator, Research support

T. M. Perl, None

J. Starke, None

A. Pavia, None

E. T. Ryan, None

R. Hasbun, None

See more of: Pre-meeting Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.